News

DRDC-funded project aims to develop recombinant human angiotensin-converting enzyme 2 (ACE2) as a potential drug candidate for COVID-19 GUELPH, Ontario, Canada, August 17, 2021 — Canadian biopharmaceutical company AntoXa Corporation has been awarded a contract extension from the Government of Canada that includes development of plant-made recombinant human angiotensin-converting enzyme ...
Continue reading ...

GUELPH, Ontario, Canada, March 20, 2019 — AntoXa Corporation has been awarded a contract with the Government of Canada to continue work on production of plant-made butyrylcholinesterase (BuChE), a protein that provides protection against toxic nerve agents such as sarin and soman. The one-year contract, worth up to $329,395, with ...
Continue reading ...

Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today that Ms. Ashley J. Meyers has been appointed President and Chief Operating Officer (COO). Ashley J. Meyers, President and COO of AntoXa Corporation. Ms. Meyers has been a member of the Canadian biopharmaceutical company’s leadership team since the company’s ...
Continue reading ...

Guelph, Ont., Canada, Nov. 28, 2018 — Ron Hosking, CPA, CA, has been appointed to the AntoXa Corporation Board of Directors, effective immediately. Mr. Hosking is a chartered accountant with three decades of experience as a financial manager in the biotechnology and pharmaceutical industries. He is also Chief Financial Officer ...
Continue reading ...

GUELPH, Ont., Canada, April 16, 2018— AntoXa Corporation has obtained a license from Defence Research & Development Canada (DRDC), an Agency of the Canadian Department of National Defence, to develop and produce an anti-ricin monoclonal antibody for sale in markets worldwide. The licensing agreement follows work AntoXa and the J.C ...
Continue reading ...